Skip to Content

LY22-02b

Main Content

Efficacy and safety of CD19 directed CAR T-cell therapy for T-cell rich histiocyte rich B-cell lymphoma.

Study #: LY22-02b

Study Status: Manuscript Preparation

Presentation(s)

2024, Tandem (Poster)